JSW Life Sciences GmbH   Report issue

For profit Phase 2 Phase 3
Founded: Grambach Austria (1999)
Status: Acquired by QPS (2012)

Organization Overview

First Clinical Trial
2005
NCT00840671
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

JSW Lifesciences | JSW Life Sciences | JSW-Life Sciences | JSW Research Forschungslabor GmbH | JSW-Research Forschungslabor GmbH, Parkring 12, 8074 Grambach

Active Ingredients

Drugs in Phase 3 Trials (2)

cenegermin-bkbj (oxervate) (1 trial)

sodium chloride (1 trial)

Drugs in Phase 2 Trials (2)

lornoxicam (1 trial)

tideglusib (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alzheimer Disease (Phase 2)

Stroke (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4